Unknown

Dataset Information

0

Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.


ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown benefits in patients with diabetes and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD).

Objective

We assessed benchmark outcomes (Hemoglobin A1c, LDL-C, and blood pressure), identified the prevalence of cardiorenal indications for SGLT2i and GLP-1RA, and compared prescribing rates of GLP1-RA and SGLT2i in those with and without cardiorenal indications.

Methods

We analyzed data from January 2018-June 2019 for 7168 patients with diabetes using electronic medical records from the Northern Alberta Primary Care Research Network, a regional network of the Canadian Primary Sentinel Surveillance Network (CPCSSN). Patients with and without cardiorenal comorbidities were compared using descriptive statistics and two proportion Z tests.

Results

Hemoglobin A1c ≤ 7.0% was met by 56.8%, blood pressure < 130/80 mmHg by 62.1%, LDL-C ≤ 2.0 mmol/L by 45.3% of patients. There were 4377 patients on glucose lowering medications; metformin was most common (77.7%), followed by insulin (24.6%), insulin secretagogues (23.6%), SGLT2i (19.7%), dipeptidyl peptidase-4 inhibitor (19.3%), and GLP-1RA (9.4%). A quarter of patients had cardiorenal indications for SGLT2i or GLP-1RA. Use of SGLT2i in these patients was lower than in patients without cardiorenal comorbidities (14.9% vs 21.2%, p < 0.05). GLP-1RA use in these patients was 4.6% compared with 11% in those without cardiorenal comorbidities (p < 0.05).

Discussion

Contrary to current evidence and recommendations, SGLT2i and GLP1-RA were less likely to be prescribed to patients with pre-existing CVD, HF, and/or CKD, revealing opportunities to improve prescribing for patients with diabetes at high-risk for worsening cardiorenal complications.

SUBMITTER: Hao R 

PROVIDER: S-EPMC9128222 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.

Hao Robin R   Myroniuk Tyler T   McGuckin Taylor T   Manca Donna D   Campbell-Scherer Denise D   Lau Darren D   Yeung Roseanne O RO  

BMC primary care 20220524 1


<h4>Background</h4>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown benefits in patients with diabetes and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD).<h4>Objective</h4>We assessed benchmark outcomes (Hemoglobin A1c, LDL-C, and blood pressure), identified the prevalence of cardiorenal indications for SGLT2i and GLP-1RA, and compared prescribing rates of GLP1-RA and SGLT2i in those with and  ...[more]

Similar Datasets

| S-EPMC9933078 | biostudies-literature
| S-EPMC4866922 | biostudies-literature
| S-EPMC7330977 | biostudies-literature
| S-EPMC11438114 | biostudies-literature
| S-EPMC9870629 | biostudies-literature
| S-EPMC11227205 | biostudies-literature
| S-EPMC8034295 | biostudies-literature
| S-EPMC4251506 | biostudies-literature
| S-EPMC4013553 | biostudies-literature
| S-EPMC11340953 | biostudies-literature